Exclusive Interviews

This week, we continue our exclusive short interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin.   Steve Freed, Publisher, Diabetes in Control: What actually brought you to taking this compound and combining it …

This week, we’re taking a break from our regularly featured section on avoiding medication mistakes to bring you this exclusive interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin. Steve Freed, Publisher, Diabetes …

This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …

Our publisher, Steve Freed, had a chance to talk with Dr. Stanley Schwartz, asking questions and getting some in-depth and very informative answers on exactly how SGLT-2 Inhibitors work.  Steve Freed: Regarding the SGLT2 drugs that are now available, I know that a lot of physicians just refuse to write …

The Future of Islet Transplantation Steve Freed: Please give tell us a little bit about yourself, and your field of interest. Dr. Eli Lewis: I studied in the medical school at Ben-Gurion University of the Negev (BGU) in Israel. During medical school, I was infatuated by medical research. I then completed …

Often, when a new class of drugs receives FDA approval, we hear from the investigators or medical professionals involved in the original studies and clinical trials and, although they may possess the most knowledge, they are often the least likely to fairly represent the opinions of most medical professionals. For …

I have been using GLP-1 analogs with my patients for the past five years and have seen many patients find reasons to stop using the medication. They complain about nausea, they complain about the cost, they say the needle hurts and they have even told me that they can’t get …

Diabetes In Control staff contacted several physicians all across the US to find out what they had to say about early insulin initiation. What they said may surprise you….

Stanley Schwartz, MD, FACP, FACE, shares his views on early insulin initiation. Insulin is the most effective agent available for lowering glycemia. If given in appropriate doses, insulin may decrease any elevated HbA1c to, or close to, the therapeutic goal. However, insulin therapy is associated with weight gain of 2 …

In a special bonus issue of our GLP-1 Special Series, we presented this excellent and informative interview with Dr. Alan Moses, Global CMO, Novo Nordisk. Dr. Moses gave us his take on the latest in GLP-1 technologies as well as a peek at Novo’s efforts in developing world-class therapies in …